A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: Suppression of CYP3A by IL-6

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 2, 2013, Pages 260-268

  MacHavaram, K K ^a   Almond, L M ^a   Rostami Hodjegan, A ^a,b   Gardner, I ^a   Jamei, M ^a   Tay, S ^c   Wong, S ^c   Joshi, A ^c   Kenny, J R ^a,c  

^a CERTARA UK LIMITED   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYTOCHROME P450 3A4; INTERLEUKIN 6; SIMVASTATIN;

AREA UNDER THE CURVE; ARTICLE; BONE MARROW TRANSPLANTATION; COMPUTER SIMULATION; CONTROLLED STUDY; DISEASE DRUG INTERACTION; DRUG INTERACTION; ENZYME REPRESSION; ENZYME SUBSTRATE; HUMAN; IN VITRO STUDY; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; RHEUMATOID ARTHRITIS;

ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; BONE MARROW TRANSPLANTATION; COMPUTER SIMULATION; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; MODELS, BIOLOGICAL; SIMVASTATIN;

EID: 84880762256     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.79     Document Type: Article

References (38)

1. Aitken, A.E., Richardson, t.A. & Morgan, E.t. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu. Rev. Pharmacol. Toxicol. 46, 123-149 (2006). (Pubitemid 43271186)
2. Morgan, E.t. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin. Pharmacol. Ther. 85, 434-438 (2009).
3. Bertilsson, P.M., Olsson, P. & Magnusson, K.E. Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cells. J. Pharm. Sci. 90, 638-646 (2001). (Pubitemid 32378385)
4. Kim, S., Östör, A.J. & Nisar, M.K. Interleukin-6 and cytochrome-P450, reason for concern? Rheumatol. Int. 32, 2601-2604 (2012).
5. Schmitt, C., Kuhn, B., Zhang, X., Kivitz, A.J. & Grange, S. Disease-drugdrug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin. Pharmacol. Ther. 89, 735-740 (2011).
6. Food and Drug Administration. Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing and Labeling Recommendations. Draft Guidance for Industry, 2012 http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm064982.htm ( U.S. Department of Health and Human Services, Centre for Drug Evaluation and Research, 2012).
7. Huang, S.M. et al. therapeutic protein-drug interactions and implications for drug development. Clin. Pharmacol. Ther. 87, 497-503 (2010).
8. Mayo, P.R., Skeith, K., Russell, A.S. & Jamali, F. Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br. J. Clin. Pharmacol. 50, 605-613 (2000). (Pubitemid 32010020)
9. Frye, R.F., Schneider, V.M., Frye, C.S. & Feldman, A.M. Plasma levels of tNFalpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J. Card. Fail. 8, 315-319 (2002). (Pubitemid 35253202)
10. Rivory, L.P., Slaviero, K.A. & Clarke, S.J. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br. J. Cancer 87, 277-280 (2002).
11. Sakamoto, K. et al. Elevation of circulating interleukin 6 after surgery: factors influencing the serum level. Cytokine 6, 181-186 (1994). (Pubitemid 24263857)
12. Perry, M.G., Kirwan, J.R., Jessop, D.S. & Hunt, L.P. Overnight variations in cortisol, interleukin 6, tumour necrosis factor alpha and other cytokines in people with rheumatoid arthritis. Ann. Rheum. Dis. 68, 63-68 (2009).
13. Knudsen, L.S. et al. Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers 13, 59-78 (2008).
14. Crofford, L.J. et al. Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J. Clin. Endocrinol. Metab. 82, 1279-1283 (1997). (Pubitemid 27166676)
15. Chung, S.J., Kwon, Y.J., Park, M.C., Park, Y.B. & Lee, S.K. the correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients. Yonsei Med. J. 52, 113-120 (2011).
16. De Benedetti, F., Massa, M., Pignatti, P., Albani, S., Novick, D. & Martini, A. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J. Clin. Invest. 93, 2114-2119 (1994).
17. Sunman, J.A., Hawke, R.L., LeCluyse, E.L. & Kashuba, A.D. Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab. Dispos. 32, 359-363 (2004). (Pubitemid 38263895)
18. Aitken, A.E. & Morgan, E.t. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab. Dispos. 35, 1687-1693 (2007). (Pubitemid 47296065)
19. Dickmann, L.J., Patel, S.K., Rock, D.A., Wienkers, L.C. & Slatter, J.G. Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drugmetabolizing enzymes in human hepatocyte culture. Drug Metab. Dispos. 39, 1415-1422 (2011).
20. Chen, Y.L. et al. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin. Pharmacol. Ther. 55, 649-660 (1994). (Pubitemid 24212266)
21. Schwinghammer, t.L. et al. the kinetics of cyclosporine and its metabolites in bone marrow transplant patients. Br. J. Clin. Pharmacol. 32, 323-328 (1991).
22. Haas, C.E., Kaufman, D.C., Jones, C.E., Burstein, A.H. & Reiss, W. Cytochrome P450 3A4 activity after surgical stress. Crit. Care Med. 31, 1338-1346 (2003). (Pubitemid 36583841)
23. Chung, E., Nafziger, A.N., Kazierad, D.J. & Bertino, J.S. Jr. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin. Pharmacol. Ther. 79, 350-361 (2006).
24. Yu, R.Z. et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin. Pharmacokinet. 48, 39-50 (2009).
25. Kyrklund, C., Backman, J.t., Kivistö, K.t., Neuvonen, M., Laitila, J. & Neuvonen, P.J. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. 68, 592-597 (2000). (Pubitemid 32059984)
26. Jones, S.C. et al. Expression of interleukin-6 by intestinal enterocytes. J. Clin. Pathol. 46, 1097-1100 (1993). (Pubitemid 24022954)
27. Lang, C.C. et al. Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism. Clin. Pharmacol. Ther. 59, 41-46 (1996). (Pubitemid 26046770)
28. Kenny, J.R. et al. therapeutic protein-drug-drug interactions: navigating the knowledge gaps. Highlights from the 2012 AAPS NBC Roundtable and Q Consortium/FDA Workshop. Chairing IQ FDA tP DI Working Group AAPS J. ( in press).
29. Lee, J.I., Zhang, L., Men, A.Y., Kenna, L.A. & Huang, S.M. CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Clin. Pharmacokinet. 49, 295-310 (2010).
30. Zhang, L., Zhang, Y.D., Zhao, P. & Huang, S.M. Predicting drug-drug interactions: an FDA perspective. AAPS J. 11, 300-306 (2009).
31. Kraynov, E. et al. How current understanding of clearance mechanisms and pharmacodynamics of therapeutic proteins can be applied for evaluation of their drug-drug interaction potential. Drug Metab. Dispos. 39, 1779-1783 (2011).
32. Roche. Actemra US prescribing information, 2013. http://www.accessdata. fda.gov/drugsat.fda-docs/label/2013/125276s064lbl.pdf
33. Vee, M.L., Lecureur, V., Stieger, B. & Fardel, O. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab. Dispos. 37, 685-693 (2009).
34. Jamei, M., Marciniak, S., Feng, K., Barnett, A., tucker, G. & Rostami-Hodjegan, A. the Simcyp population-based ADME simulator. Expert Opin. Drug Metab. Toxicol. 5, 211-223 (2009).
35. Rowland Yeo, K., Jamei, M., Yang, J., tucker, G.t. & Rostami-Hodjegan, A. Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-the effect of diltiazem on the time-course of exposure to triazolam. Eur. J. Pharm. Sci. 39, 298-309 (2010).
36. Sanada, H., Sekimoto, M., Kamoshita, A. & Degawa, M. Changes in expression of hepatic cytochrome P450 subfamily enzymes during development of adjuvant-induced arthritis in rats. J. Toxicol. Sci. 36, 181-190 (2011).
37. Uno, S., Kawase, A., tsuji, A., tanino, t. & Iwaki, M. Decreased intestinal CYP3A and P-glycoprotein activities in rats with adjuvant arthritis. Drug Metab. Pharmacokinet. 22, 313-321 (2007).
38. Rowland Yeo, K., Walsky, R.L., Jamei, M., Rostami-Hodjegan, A. & tucker, G.t. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. Eur. J. Pharm. Sci. 43, 160-173 (2011).